# Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

> **NCT06677229** · PHASE1,PHASE2 · RECRUITING · sponsor: **Technophage, SA** · enrollment: 28 (estimated)

## Conditions studied

- Acute Spinal Cord Injury (SCI)

## Interventions

- **DRUG:** Eletriptan HBr 40 mg

## Key facts

- **NCT ID:** NCT06677229
- **Lead sponsor:** Technophage, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677229, "Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06677229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*